UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Denosumab Versus Risedronate in Glucocorticoid‐Induced Osteoporosis: Final Results of a Twenty‐Four–Month Randomized, Double‐Blind, Double‐Dummy Trial

Arthritis & rheumatology (Hoboken, N.J.), 2019-07, Vol.71 (7), p.1174-1184

2019

Volltextzugriff (PDF)

Calcium Metabolism and Correcting Calcium Deficiencies

Endocrinology and metabolism clinics of North America, 2012-09, Vol.41 (3), p.527-556

2012

Volltextzugriff (PDF)

Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women

The New England journal of medicine, 2004-03, Vol.350 (12), p.1189-1199

2004

Volltextzugriff (PDF)

Improving Compliance and Persistence with Bisphosphonate Therapy for Osteoporosis

The American journal of medicine, 2006-04, Vol.119 (4), p.S18-S24

2006

Volltextzugriff (PDF)

Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO)

Current medical research and opinion, 2005-12, Vol.21 (12), p.1895-1903

2005

Volltextzugriff (PDF)

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial

Annals of internal medicine, 2002-12, Vol.137 (11), p.875

2002

Volltextzugriff (PDF)

Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial

Journal of rheumatology, 2004-01, Vol.31 (1), p.150

2004

Volltextzugriff (PDF)

Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: Results of a meta-analysis

Bone (New York, N.Y.), 2009-03, Vol.44 (3), p.423-427

2009

Volltextzugriff (PDF)

Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis

The New England journal of medicine, 1998-07, Vol.339 (5), p.292-299

1998

Volltextzugriff (PDF)

Efficacy and Safety of Oral Weekly Ibandronate in the Treatment of Postmenopausal Osteoporosis

The journal of clinical endocrinology and metabolism, 2003-10, Vol.88 (10), p.4609-4615

2003

Volltextzugriff (PDF)

Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis

The American journal of medicine, 1996-11, Vol.101 (5), p.488-501

1996

Volltextzugriff (PDF)

Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study

The lancet. Diabetes & endocrinology, 2018-06, Vol.6 (6), p.445-454

2018

Volltextzugriff (PDF)

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): Additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study

Clinical therapeutics, 2009-04, Vol.31 (4), p.751-761

2009

Volltextzugriff (PDF)

Quarterly intravenous ibandronate for postmenopausal osteoporosis

Women's health (London, England), 2008-05, Vol.4 (3), p.219-228

Emkey, Ronald D

2008

Volltextzugriff (PDF)

Safety considerations with bisphosphonates for the treatment of osteoporosis

Drug safety, 2007-01, Vol.30 (9), p.755-763

2007

Volltextzugriff (PDF)

Use of Bone Alkaline Phosphatase to Monitor Alendronate Therapy in Individual Postmenopausal Osteoporotic Women

Clinical chemistry (Baltimore, Md.), 1999-07, Vol.45 (7), p.1009-1017

1999

Volltextzugriff (PDF)

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

The Lancet (British edition), 2009-04, Vol.373 (9671), p.1253-1263

2009

Volltextzugriff (PDF)

Calcium Metabolism and Correcting Calcium Deficiencies: Osteoporosis

Endocrinology and metabolism clinics of North America, 2012, Vol.41 (3)

2012

Volltextzugriff (PDF)

Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene

Menopause (New York, N.Y.), 2006-05, Vol.13 (3), p.377-386

2006

Volltextzugriff (PDF)

Skeletal benefits of alendronate : 7-year treatment of postmenopausal osteoporotic women

The journal of clinical endocrinology and metabolism, 2000-09, Vol.85 (9), p.3109-3115

2000

Volltextzugriff (PDF)

Improving compliance and persistence with bisphosphonate therapy for osteoporosis: Improving Compliance and Persistence with Osteoporosis Therapies

The American journal of medicine, 2006, Vol.119 (4A)

2006

Volltextzugriff (PDF)

Ten Years’ Experience With Alendronate for Osteoporosis in Postmenopausal Women

Obstetrical & gynecological survey, 2004-08, Vol.59 (8), p.597-598

2004

Volltextzugriff (PDF)

Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE

Current medical research and opinion, 2005-03, Vol.21 (3), p.391-401

2005

Volltextzugriff (PDF)

Ibandronate: once-monthly and intravenous dosing options for osteoporosis treatment

Women's health (London, England), 2006-05, Vol.2 (3), p.341-349

Emkey, Ronald

2006

Volltextzugriff (PDF)

Oral ibandronate reduces non-vertebral fracture risk in postmenopausal osteoporosis: Results from a sub-analysis of a pivotal study

Bone (New York, N.Y.), 2008-03, Vol.42, p.S86-S86

2008

Volltextzugriff (PDF)

1 – 25 von 62

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(49)

Publikationsform

Artikel
(61)
Referenzeintrag
(1)

Sprache

Englisch
(62)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(37)
Science & Technology
(37)
Humans
(35)
Female
(29)
Biological And Medical Sciences
(23)
Medical Sciences
(23)
Middle Aged
(23)
Aged
(22)
Double-Blind Method
(18)
Pharmacology. Drug Treatments
(15)
Male
(14)
Osteoporosis
(14)
Osteoporosis, Postmenopausal - Drug Therapy
(13)
Bone Density - Drug Effects
(12)
Bones, Joints And Connective Tissue. Antiinflammatory Agents
(12)
General & Internal Medicine
(11)
Medicine, General & Internal
(11)
Rheumatology
(11)
Treatment Outcome
(10)
Adult
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Denosumab Versus Risedronate in Glucocorticoid‐Induced Osteoporosis: Final Results of a Twenty‐Four–Month Randomized, Double‐Blind, Double‐Dummy Trial

Calcium Metabolism and Correcting Calcium Deficiencies

Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women

Improving Compliance and Persistence with Bisphosphonate Therapy for Osteoporosis

Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO)

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial

Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial

Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: Results of a meta-analysis

Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis

Efficacy and Safety of Oral Weekly Ibandronate in the Treatment of Postmenopausal Osteoporosis

Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis

Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): Additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study

Quarterly intravenous ibandronate for postmenopausal osteoporosis

Safety considerations with bisphosphonates for the treatment of osteoporosis

Use of Bone Alkaline Phosphatase to Monitor Alendronate Therapy in Individual Postmenopausal Osteoporotic Women

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

Calcium Metabolism and Correcting Calcium Deficiencies: Osteoporosis

Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene

Skeletal benefits of alendronate : 7-year treatment of postmenopausal osteoporotic women

Improving compliance and persistence with bisphosphonate therapy for osteoporosis: Improving Compliance and Persistence with Osteoporosis Therapies

Ten Years’ Experience With Alendronate for Osteoporosis in Postmenopausal Women

Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE

Ibandronate: once-monthly and intravenous dosing options for osteoporosis treatment

Oral ibandronate reduces non-vertebral fracture risk in postmenopausal osteoporosis: Results from a sub-analysis of a pivotal study

Suchergebnisse filtern